Cargando…

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin(®) with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology

BACKGROUND: A biosimilar needs to demonstrate its similarity to the originator reference product (RP) in terms of structural and functional properties as well as nonclinical and clinical outcomes. OBJECTIVES: The aim was to assess the analytical similarity between the trastuzumab biosimilar HLX02 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Liqi, Zhang, Erhui, Xu, Yanpeng, Gao, Wenyuan, Wang, Linlin, Xie, Michael Hongwei, Qin, Peilan, Lu, Lihong, Li, Sipeng, Shen, Pengcheng, Jiang, Weidong, Liu, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211197/ https://www.ncbi.nlm.nih.gov/pubmed/32072477 http://dx.doi.org/10.1007/s40259-020-00407-0

Ejemplares similares

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
por: Xu, Yanpeng, et al.
Publicado: (2019)

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
por: Hurst, Susan, et al.
Publicado: (2014)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
por: Akbarzadeh-Sharbaf, Soudabeh, et al.
Publicado: (2012)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant
por: Phaahla, Ntando G., et al.
Publicado: (2019)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

Safety of trastuzumab (Herceptin(®)) during pregnancy: two case reports
por: Goodyer, Matthew J, et al.
Publicado: (2009)

Role of N-Glycosylation in FcγRIIIa interaction with IgG
por: Van Coillie, Julie, et al.
Publicado: (2022)

The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation
por: Shibata-Koyama, Mami, et al.
Publicado: (2009)

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa(V158) Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
por: Kang, Tae Hyun, et al.
Publicado: (2019)

Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors
por: Isoda, Yuya, et al.
Publicado: (2015)

FcγRIIa and FcγRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia
por: Zakaria, Marwa, et al.
Publicado: (2023)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2015)

TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin(®) and US‐Herceptin(®) in healthy male subjects
por: Demarchi, Martin, et al.
Publicado: (2021)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2016)

Phosphatidylinositol-3 kinase activation induced upon Fc gamma RIIIA- ligand interaction
Publicado: (1994)

Biophysical Characterization of the Contribution of the Fab Region to the IgG-FcγRIIIa Interaction
por: Kosuge, Hirofumi, et al.
Publicado: (2022)

Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC
por: Mao, Changchuin, et al.
Publicado: (2021)

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index
por: Karimifar, Mansoor, et al.
Publicado: (2021)

Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI
por: Liang, Jianye, et al.
Publicado: (2022)

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial
por: Xu, Binghe, et al.
Publicado: (2021)

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index
por: Karimifar, Mansoor, et al.
Publicado: (2022)

The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy
por: Fox, K F
Publicado: (2006)

A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin(®) (EU) in healthy adult males
por: Lickliter, Jason D., et al.
Publicado: (2021)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids
por: Cox, Freek, et al.
Publicado: (2016)

FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV
por: Talathi, Sneha Pramod, et al.
Publicado: (2019)

Oligomannose N-Glycans 3D Architecture and Its Response to the FcγRIIIa Structural Landscape
por: Fogarty, Carl A, et al.
Publicado: (2021)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
por: ROŽMAN, SAMO, et al.
Publicado: (2016)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t34r6pce9s8r8dd336rsldotna